Phase III trial evaluating letrozole as first-line endocrine therapy with or without bevacizumab for the treatment of postmenopausal women with hormone receptor-positive advanced-stage breast cancer: CALGB 40503 (Alliance) Journal Article
| Authors: | Dickler, M. N.; Barry, W. T.; Cirrincione, C. T.; Ellis, M. J.; Moynahan, M. E.; Innocenti, F.; Hurria, A.; Rugo, H. S.; Lake, D. E.; Hahn, O.; Schneider, B. P.; Tripathy, D.; Carey, L. A.; Winer, E. P.; Hudis, C. A. |
| Article Title: | Phase III trial evaluating letrozole as first-line endocrine therapy with or without bevacizumab for the treatment of postmenopausal women with hormone receptor-positive advanced-stage breast cancer: CALGB 40503 (Alliance) |
| Abstract: | Purpose To investigate whether anti-vascular endothelial growth factor therapy with bevacizumab prolongs progression-free survival (PFS) when added to first-line letrozole as treatment of hormone receptor-positive metastatic breast cancer (MBC). Patients and Methods Women with hormone receptor-positive MBC were randomly assigned 1:1 in a multicenter, openlabel, phase III trial of letrozole (2.5 mg orally per day) with or without bevacizumab (15 mg/kg intravenously once every 3 weeks) within strata defined by measurable disease and disease-free interval. This trial had 90% power to detect a 50% improvement in median PFS from 6 to 9 months. Using a one-sided alpha = .025, a target sample size of 352 patients was planned. Results From May 2008 to November 2011, 350 women were recruited; 343 received treatment and were observed for efficacy and safety. Median age was 58 years (range, 25 to 87 years). Sixty-two percent had measurable disease, and 45% had de novo MBC. At a median follow-up of 39 months, the addition of bevacizumab resulted in a significant reduction in the hazard of progression (hazard ratio, 0.75; 95% CI, 0.59 to 0.96; P = .016) and a prolongation in median PFS from 15.6 months with letrozole to 20.2 months with letrozole plus bevacizumab. There was no significant difference in overall survival (hazard ratio, 0.87; 95% CI, 0.65 to 1.18; P = .188), with median overall survival of 43.9 months with letrozole versus 47.2 months with letrozole plus bevacizumab. The largest increases in incidence of grade 3 to 4 treatment-related toxicities with the addition of bevacizumab were hypertension (24% v2%) and proteinuria (11% v 0%). Conclusion The addition of bevacizumab to letrozole improved PFS in hormone receptor-positive MBC, but this benefit was associated with a markedly increased risk of grade 3 to 4 toxicities. Research on predictive markers will be required to clarify the role of bevacizumab in this setting. (C) 2016 by American Society of Clinical Oncology (C) 2016 by American Society of Clinical Oncology |
| Keywords: | estrogen; tamoxifen; first-line therapy; double-blind; endothelial growth-factor; randomized-trial; combination; factor expression; plus bevacizumab; adjuvant bevacizumab |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 34 |
| Issue: | 22 |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2016-08-01 |
| Start Page: | 2602 |
| End Page: | 2609 |
| Language: | English |
| ACCESSION: | WOS:000382465300008 |
| DOI: | 10.1200/jco.2015.66.1595 |
| PROVIDER: | wos |
| PMCID: | PMC5012690 |
| PUBMED: | 27138575 |
| Notes: | Article -- Source: Wos |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work